Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.78
+1.08 (5.78%)
At close: Apr 17, 2026, 4:00 PM EDT
19.95
+0.17 (0.84%)
After-hours: Apr 17, 2026, 7:48 PM EDT
Monte Rosa Therapeutics Revenue
In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth. Monte Rosa Therapeutics had revenue of $2.78M in the quarter ending December 31, 2025, a decrease of -95.41%.
Revenue (ttm)
$123.67M
Revenue Growth
+63.54%
P/S Ratio
12.80
Revenue / Employee
$824,480
Employees
150
Market Cap
1.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Iovance Biotherapeutics | 263.50M |
| Viridian Therapeutics | 70.85M |
| Immatics | 56.67M |
| Nanobiotix | 38.27M |
| AtaiBeckley | 4.09M |
GLUE News
- 4 weeks ago - Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewsWire